Ignyta is a personalized medicine company developing biomarker‑based diagnostic tests for rheumatoid arthritis, lupus and other autoimmune diseases. The company is focused on an objective biomarker test to help detect rheumatoid arthritis in its earliest stages. Ignyta applies “omics” technologies integrated with bioinformatics to develop and commercialize novel diagnostics. The company was launched in August 2011 by Jonathan E. Lim, M.D. and Gary S. Firestein, M.D., and is based in San Diego, California. Scientific discoveries underpinning the company were published in July 2012. Financially, Ignyta completed a $5.5 million Series B financing in 2012 and has supplemented equity with venture debt from Silicon Valley Bank. Ignyta develops the Enlyta suite of molecular diagnostic assays aimed at improving diagnosis and treatment decisions for rheumatoid arthritis, lupus and other autoimmune diseases. The company positions itself in personalized medicine by improving biomarker quality and identifying novel autoimmune disease targets for biopharmaceutical partners. Management, led by co-founder and CEO Jonathan Lim, intends to use the new capital to advance Enlyta toward commercialization and to initiate clinical studies to validate an RA diagnostic assay at early, treatable stages. Ignyta also plans to prepare for CLIA certification of its diagnostic laboratory to support commercialization targeted for late 2014 or early 2015. Financially, the company completed an expanded Series B equity financing totaling $5.5M and received a $500K capital term loan from Silicon Valley Bank to support these activities. The company is based in San Diego, CA.

Total raised

$7M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Feb 2013